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Abstract
 
Somatic hypermutation (SHM) and class switch recombination (CSR) are initiated in activated
B lymphocytes by activation-induced deaminase (AID). AID is thought to make lesions in
DNA by deaminating cytidine residues in single-stranded DNA exposed by RNA polymerase
during transcription. Although this must occur in the nucleus, AID is found primarily in the
cytoplasm. Here we show that AID is actively excluded from the nucleus by an exportin
CRM1-dependent pathway. The AID nuclear export signal (NES) is found at the carboxyl
terminus of AID in a region that overlaps a sequence required for CSR but not SHM. We find
that AID lacking a functional NES causes more hypermutation of a nonphysiologic target gene
in transfected fibroblasts. However, the NES does not impact on the rate of mutation of immu-
noglobulin genes in B lymphocytes, suggesting that the AID NES does not limit AID activity
in these cells.
Key words: somatic hypermutation • activation-induced deaminase • 
nucleo-cytoplasmic trasnport • B lymphocytes • Ig class switching
 
Introduction
 
In the course of immune responses, two distinct DNA
modification reactions, somatic hypermutation (SHM)
and class switch recombination (CSR), diversify antibody
genes. SHM introduces mutations into the variable region
exons of antibody genes thereby producing a set of variant
antibodies that can be selected on the basis of antigen-binding
affinity (1). CSR is a DNA recombination reaction that
joins two Ig switch regions by deletion of intervening se-
quences. This diversifies antibody responses by producing
related clones of B cells where a single variable region exon
is combined with different constant region exons with
unique effector functions (2–6).
Despite the clear differences in the DNA modification
processes that result in SHM and CSR, both reactions appear
to be initiated by a single enzyme, activation-induced
deaminase (AID). AID is expressed specifically in activated
B cells that undergo CSR and SHM and it is essential for
both reactions in humans and mice (7–9). Further, AID is
the only B cell–specific factor required for SHM and CSR
because both reactions can be induced in fibroblasts trans-
fected with AID (10–12).
AID is homologous to APOBEC-1, an mRNA editing
cytidine deaminase, and it was first proposed that AID
might initiate SHM or CSR indirectly by editing mRNA
to create a novel nuclease (7, 8). An alternative possibility is
that AID initiates SHM and CSR by deaminating cytidines
in DNA (13). Cytidine deaminated to uridine could be
replicated to produce a transition mutation (13) or be repaired
by the mismatch repair pathway (14–20). Alternatively, the
mismatched uracil could be removed by uracil-DNA glyco-
sylase to produce an abasic site that might be processed by
nucleases and error-prone polymerases to cause SHM or
CSR (19–24).
The DNA deamination hypothesis is supported by cell
biologic, genetic, and biochemical studies (13, 19, 20, 25–30).
AID–estrogen receptor fusion proteins are only active
when they are targeted to the nucleus (29), and AID is
physically associated with Ig switch region DNA in B cells
undergoing CSR (31). Mutations that result in loss of
DNA uracil-DNA glycosylase activity interfere with SHM
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and CSR in 
 
Escherichia coli
 
, chicken DT40 cell lines, and
mice (13, 19, 20). Biochemical experiments show that AID
binds single-stranded DNA (ssDNA), that it deaminates cy-
tidine residues in ssDNA in vitro (26–28), and that it is re-
quired for switch region break formation (30). Finally,
experiments in 
 
E. coli
 
 have shown that AID deaminates
ssDNA exposed by RNA polymerase during transcription,
consistent with the known link between transcription and
SHM (25). Thus, the available evidence favors the DNA
deamination hypothesis but fails to account for the cyto-
plasmic localization of AID.
Appropriate cellular localization is a key event for the
proper physiological function of proteins. Movement of
proteins to and from the nucleus occurs through nuclear
pore complexes (for review see references 32 and 33). The
nuclear pore complexes allow passive diffusion of mole-
cules up to 
 
 
 
60 kD in size into and out of the nucleus,
whereas transport of larger proteins requires soluble shut-
tling receptors that recognize nuclear localization signals
(NLSs) or nuclear export signals (NESs) for movement into
or out of the nucleus, respectively (34, 35). CRM1 (chro-
mosome region maintenance/exportin 1) is a ubiquitous
soluble shuttling receptor that binds leucine-rich NESs and
translocates them out of the nucleus (34, 35). CRM1 facil-
itates active export by interacting directly with the Ran
GTPase and nuclear pore components.
AID has been observed to localize to the cytoplasm with
exclusion from the nucleus (36). Here we report that AID
contains an NES recognized by CRM1 that prevents it
from accumulating in the nucleus. The AID NES is found
at the C terminus of AID in a region that is required for
CSR but not SHM.
 
Materials and Methods
 
Mouse B Cell Cultures and Retroviral Infection.
 
Wild-type or
AID
 
 
 
/
 
  
 
B cells were purified from mouse spleen by depletion
with anti-CD43 magnetic beads (Miltenyi Biotec) and cultured
in RPMI 1640 medium with 5 ng/ml IL-4 plus LPS (Sigma-
Aldrich). Retroviral supernatants for mouse B cell infection were
obtained by cotransfecting BOSC 23 cells with pMX-PIE and
pCL-ECO plasmids using Fugene 6 (Roche; reference 37). Su-
pernatants were harvested 24 h after transfection and used to in-
fect B cells that had been cultured in LPS plus IL-4 for 1 d. 1 d
after infection, the retroviral supernatant was replaced. Infection
efficiency was in the range of 30% as determined by green fluo-
rescent protein (GFP) expression. Retroviruses for infecting 3T3-
NTZ cells (12) were produced using pQCXIP and pCL-ECO
plasmids (CLONTECH Laboratories, Inc.). 3T3-NTZ were cul-
tured in the absence of tetracycline and selected in puromycin
starting 1 d after infection. All assays on 3T3-NTZ cells were
performed on puromycin-selected cells.
 
Flow Cytometry and Cell Sorting.
 
Mouse B cells were stained
with biotinylated anti–mouse IgG1 antibodies and visualized with
streptavidin PE-Cy7 (Becton Dickinson) 72 h after infection
with retrovirus. Data was acquired on a FACSCalibur™ and ana-
lyzed with the CELLQuest™ software, FACSCalibur™ (both
from Becton Dickinson). GFP
 
  
 
and IgG1
 
  
 
cells were sorted on a
FACS Vantage™ SE cell sorter (BD Immunocytometry Systems).
GFP expression in 3T3-NTZ cells was analyzed on a FACSCali-
bur™ as previously described (12).
 
PCR and Mutation Analysis.
 
Switch 
 
  
 
region genomic DNA
was amplified from 100,000 sorted cells by PCR using Pfu Turbo
DNA polymerase (Stratagene). Amplification conditions were 25
cycles at 94
 
 
 
C for 30 s, 60
 
 
 
C for 30 s, and 72
 
 
 
C for 40 s. Prim-
ers were 
 
  
 
switch region: 5
 
 
 
-570 (5
 
 
 
-GGGTTTGAATTTT-
GAATCTATTCTG-3
 
 
 
) and S
 
 
 
R5 (5
 
 
 
-GCGGCCCGGCTCA-
TTCCAGTTCATTACAG-3
 
 
 
; reference 38). These amplify
GenBank/EMBL/DDBJ accession number 109111111–109111733
of mouse chromosome 12 and do not discriminate between germ-
line and recombined switch 
 
  
 
region. For mutational analysis,
the GFP gene from NTZ-3T3 DNA was amplified 3 d after in-
fection using Pfu Turbo polymerase. Amplification conditions
were 25 cycles at 94
 
 
 
C for 30 s, 57
 
 
 
C for 30 s, and 72
 
 
 
C for 1
min (12) using the primers CMVPF (5
 
 
 
-TGACCTCCATA-
GAAGACACCG-3
 
 
 
) and TetGFPR (5
 
 
 
-TTATGTTTCAGGT-
TCAGGGGG-3
 
 
 
). PCR products were cloned using TOPO-TA
cloning kit (Invitrogen) and sequenced using T7 universal prim-
ers. Sequence analysis was performed using Sequence Manager II
software (DNASTAR).
 
Microscopy.
 
293 cells were plated on glass coverslips, trans-
fected with GFP fusion constructs, and evaluated 48 h after trans-
fection. Cells were fixed with 4% formaldehyde and made perme-
able with 0.1% Triton X-100. Nuclear membranes were stained
with mAb-414 (39) and visualized by donkey anti–mouse Alexa
Fluor 555 (Molecular Probes). Micrographs were produced using
a Carl Zeiss MicroImaging, Inc. LSM 510 confocal microscope.
AID
 
 
 
/
 
  
 
B cells were infected with pQCXIP AID-GFP retrovirus
48 h before staining and evaluation. Leptomycin B (LMB; Sigma-
Aldrich) treatment was for 1 h at 10 ng/ml before fixation.
 
Plasmid Constructs and E. coli Assays.
 
Pyruvate kinase (PK) or
PK fused to the NLS from the human K protein (PKNLS; refer-
ence 40) was fused to the amino terminus of GFP and cloned
into pCDNA3 (Invitrogen). Murine AID or its variants were
fused to the carboxyl terminus of GFP with a GGST linker to
produce PK-GFP-AID or PKNLS-GFP. To produce NES-GFP
or AID
 
188–198
 
-GFP, a double-stranded oligonucleotide corre-
sponding to MAPKK NES (MDLQKKLEELELDE) or AID
NES (MDLRDAFRMLGF) was fused to the amino terminus of
GFP. Retroviral expression constructs were produced by insert-
ing AID or AID fused to the amino terminus of GFP (AID-GFP)
into pMX-PIE or pQCXIP (CLONTECH Laboratories, Inc.).
 
E. coli
 
 assays were performed exactly as previously described (25).
 
Protein Analysis.
 
Rabbit AID antibody was produced using a
peptide derived from the carboxyl terminus of AID (EVDDL-
RDAFRMLGF) coupled to keyhole limpet haemocyanin. For
Western blot assays, cells were lysed in 50 mM Tris, pH 8.0, 400
mM NaCl, 0.5% NP-40, 10% glycerol. Western blots were per-
formed on 40 ug protein using the anti-AID antibody or anti-PK
antibody (Polysciences Inc.), and normalized based on PK and
GFP expression in infected B cells, PK in puromycin-selected
3T3-NTZ cells, or total cell protein in 
 
E. coli
 
.
 
Results
 
AID Contains an NES.
 
To determine whether cellular
localization of AID is actively regulated, we made use of a
PK-GFP reporter (PK-GFP; reference 40). PK-GFP is
found in the cytoplasm of transfected 293 cells because it
lacks an NLS and is too large to pass through nuclear pores
by diffusion (Fig. 1; references 40 and 41). We found that 
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addition of AID to PK-GFP (PK-GFP-AID) produced a
protein that like PK-GFP, localizes to the cytoplasm (Fig.
1). Addition of an exogenous NLS to the PK-GFP indica-
tor (PKNLS-GFP) targets the chimeric protein to the cell
nucleus where it remains because PKNLS-GFP lacks an
NES (40). However, PKNLS-GFP-AID differed from
PKNLS-GFP in that it remained cytoplasmic despite the
NLS, suggesting that AID either anchors the chimeric pro-
tein to the cytoplasm or that it is actively exported from the
nucleus (Fig. 1).
To determine if nuclear export controls PKNLS-GFP-
AID exclusion from the nucleus, we treated cells with the
CRM1 exportin inhibitor LMB (42). Treatment of PKNLS-
GFP-AID–expressing cells with LMB for 1 h caused a dra-
matic shift in reporter localization from cytoplasm to nucleus
(Fig. 1). However, LMB treatment had no effect on cells ex-
pressing control reporters without the NLS or AID (Fig. 1,
PK-GFP-AID and PKNLS-GFP, respectively). The nearly
complete nuclear accumulation of PKNLS-GFP-AID after
LMB treatment indicates that cytoplasmic localization of
PKNLS-GFP-AID is due to AID-dependent CRM1-medi-
ated nuclear export. Thus, AID contains an NES that ac-
tively regulates its subcellular localization.
To define the AID NES, we systematically deleted
amino acids from the carboxyl and amino terminus of AID
and tested the mutant proteins in combination with the
PKNLS-GFP reporter (unpublished data). We found that
the last 10 residues of AID are essential for export and that
deletion of these residues (PKNLS-GFP-AID
 
 
 
188–198
 
) re-
sulted in nuclear accumulation of the reporter as opposed
to cytoplasmic localization of the intact reporter (Fig.
1, compare PKNLS-GFP-AID
 
 
 
188–198 
 
and PKNLS-GFP-
AID). Proteins transported by CRM1 have an NES charac-
terized by a short peptide sequence rich in leucine or hy-
drophobic residues, and alignment of authentic NESs with
residues 188–198 of AID reveals that the sequence con-
forms to an NES consensus (Table I; reference 43). To
confirm that AID
 
188–198 
 
is an NES, we made a point muta-
tion changing phenylalanine198 to alanine AID
 
F198A 
 
and
tested the mutant AID in our nuclear export assay as a
fusion protein (PKNLS-GFP-AID
 
F198A
 
). We found that
PKNLS-GFP-AID
 
F198A 
 
had no export activity in trans-
fected 293 cells and showed nuclear accumulation similar
to PKNLS-GFP-AID
 
 
 
188–198 
 
(Fig. 1). We conclude that the
sequence between amino acids 188–198 in AID contains
an active NES.
To determine whether AID has an endogenous NLS, we
removed the exogenous NLS from PKNLS-GFP-AID
 
F198A
Figure 1. AID has an NES. Diagrams at right (not to scale) show trans-
fected indicator constructs.  LMB indicates that transfected cells were
treated with 10 nM LMB for 1 h. Representative confocal micrographs
show 293 cells expressing green GFP and red nuclear membranes stained
with fluorescent anti-nuclear pore (NUP) antibodies.
 
Table I.
 
Alignment of AID Residues with Authentic NESs
 
AID 188 D
 
L
 
RDA
 
F
 
RM
 
L
 
G
 
F
 
198
MAPKK A
 
L
 
QKK
 
L
 
EE
 
L
 
E
 
L
 
PKI
 
 
 
E
 
L
 
ALK
 
L
 
AG
 
L
 
D
 
I
 
STAT1 S
 
L
 
AAE
 
F
 
RH
 
L
 
Q
 
L
 
Cyclin B D
 
L
 
CQA
 
F
 
SD
 
V
 
L
 
I
 
HIV-Rev
 
L
 
Q
 
L
 
PP
 
L
 
ER
 
L
 
T
 
L
 
Conserved leucines and hydrophobic amino acids critical to NES function
are in bold. 
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to produce PK-GFP-AID
 
F198A 
 
(Fig. 1). In contrast to
PKNLS-GFP-AID
 
F198A
 
, which is constitutively imported
and trapped in the nucleus because it lacks an NES, PK-
GFP-AID
 
F198A 
 
was found in the cytoplasm of transfected
cells. Consistent with this finding, inhibition of CRM1 by
LMB in cells transfected with PK-GFP-AID also failed to
show nuclear accumulation of the indicator (Fig. 1). We
conclude that AID does not have a constitutive NLS capable
of actively transporting PK fusion proteins into the nucleus.
To ensure that the amino terminal fusions of GFP to
AID did not interfere with normal localization, we fused
GFP to the carboxyl terminus of AID (AID-GFP) and ex-
pressed it in 293 cells (Fig. 1). As reported by others, AID-
GFP was found in the cytoplasm (36, 44). Mutation of the
NES (AID
 
F198A
 
-GFP) resulted redistribution to the cyto-
plasm and nuclear compartments. This localization is con-
sistent with passive diffusion because the size of this
chimeric protein (50 kD) is less then the nuclear pore ex-
clusion limit. Thus, we do not detect a constitutive NLS in
AID regardless of the GFP tag location.
To determine whether AID
 
188–198 
 
can function as an au-
tonomous NES, we fused it directly to GFP. GFP is small
enough to diffuse freely through nuclear pores and is found
in both nucleus and cytoplasm (Fig. 2). Addition of AID
 
188–198
 
peptide to GFP (AID
 
188–198
 
-GFP) resulted in nuclear ex-
clusion similar to that of GFP fused with an authentic NES
peptide from MAPKK (Fig. 2, NES-GFP), and a point
mutation changing phenylalanine 198 to alanine inacti-
vated nuclear exclusion (Fig. 2, AID
 
188–198, F198A
 
-GFP). Fi-
nally, the AID NES mediates nuclear export by the CRM1
pathway because LMB treatment reversed the nuclear
Figure 2. AID residues 188–198 comprise a functional NES. Diagrams
show maps (not to scale) of transfected indicator constructs.  LMB indicates
that transfected cells were treated with 10 nM LMB for 1 h. Representative
confocal micrographs show 293 cells expressing green GFP and red nuclear
membranes stained with fluorescent anti-NUP antibodies.
Figure 3. Nuclear export controls AID localization in B cells. (A) Retrovi-
ral vector used to infect B cells. (B) AID-GFP or AIDF198A-GFP expressed
in LPS and IL-4–stimulated AID /  B cells after retroviral infection. Dia-
grams (not to scale) of indicator constructs (right). Representative confo-
cal micrographs show green GFP and red nuclear membranes stained
with fluorescent anti-NUP antibodies.
Figure 4. SHM by NES mutant AID in E. coli. (A) AID, AIDF198A, and
AIDL62A (a catalytically inactive control; reference 25) protein expression
in E. coli measured by Western blotting with rabbit anti–AID antiserum.
(B) SHM measured by Kan-resistance assay for AID-mediated cytidine
deamination in UDG (uracil DNA glycosylase)-deficient E. coli. Circles
represent the mutation frequency of individual starting colonies and hori-
zontal bars represent mean values. Results from two independent experi-
ments are shown. Mean frequencies of KanR colonies are indicated un-
derneath each group. 
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level of mutator activity (Fig. 4 B; AID
 
F198A 
 
  
 
1.7 
 
  
 
AID,
P 
 
  
 
0.027). We conclude that AID
 
F198A 
 
is marginally more
active than wild-type AID.
To determine whether nuclear export in eukaryotic cells
regulates SHM, we used 3T3-NTZ indicator cells, which
carry an actively transcribed GFP gene with a premature
stop codon whose reversion can be assayed by flow cytom-
etry (12, 45). AID expression in 3T3-NTZ initially induces
GFP fluorescence, but prolonged AID expression inacti-
vates GFP by accumulation of deleterious mutations (12).
Although AID
 
F198A 
 
was expressed at 3.6-fold lower levels
than AID by Western blotting (Fig. 5 B), AID
 
F198A
 
-
infected 3T3-NTZ cells initially showed greater SHM
than AID-infected cells (Fig. 5 C). At later time points the
percentage of GFP expression by AID
 
F198A
 
-infected 3T3-
NTZ cells leveled off and then decreased relative to wild-
type AID (Fig. 5 C). To determine whether this pattern of
GFP expression was due to increased SHM, we sequenced
the GFP gene from AID and AID
 
F198A
 
-expressing 3T3-
NTZ cells 3 d after infection. Relative to AID
 
F198A
 
, AID
showed a small increase in the number of mutated GFP
genes (35 vs. 51%, respectively, P   0.08) and a significant
increase in the number of mutations per GFP gene (Fig. 5
D). The average number of mutations per mutated clone in
AIDF198A was 4.4 compared with 1.5 for AID (Fig. 5 D,
P   0.003), with a maximum of 3 mutations per clone
Figure 5. SHM by NES-mutant AID in transfected fibroblasts. (A) Diagrammatic representation of retroviral vector used to infect 3T3-NTZ cells. (B) AID
and AIDF198A protein expression in 3T3-NTZ cells after 3 d of culture measured by Western blotting of 15  g whole cell extracts. Anti-PK Western blot
served as a loading control. (C) Percent of GFP expressing 3T3-NTZ cells measured by flow cytometry (y axis) and plotted over time in days (x axis).
Results show mean of triplicate cultures from one of n   5 representative experiments. (D) Proportion of GFP sequences cloned from AID or AIDF198A-
expressing 3T3-NTZ cells 3 d after infection carrying a different number of mutations. Segment sizes in the pie charts are proportional to the number of
sequences carrying the number of mutations indicated in the periphery of the charts. The total number of independent sequences analyzed is indicated in
the center of each chart. Deletions, duplications, and insertions were excluded from this analysis. (E) Comparison of GFP gene sequences cloned from
AID or AIDF198A-expressing 3T3-NTZ cells after 3 d of culture. Single nucleotide substitutions are indicated above AID or below AIDF198A, the authentic
GFP sequence. Bold indicates deletions and boxes indicate WRC (R, purine; W, A or T) hotspots (reference 70) are underlined.
exclusion of AID188–198-GFP (Fig. 2). We conclude that
AID188–198 constitutes an NES recognized by CRM1.
The CRM1 export pathway is found in all cell types, but
B cells may have specific factors that control the nucleo-
cytoplasmic movement of AID. To examine the regulation of
AID in B cells undergoing CSR, AID-GFP or AIDF198A-
GFP was expressed in LPS plus IL-4–stimulated AID /  B
cells by retrovirus infection. 48 h after infection, AID-GFP
was localized in the cytoplasm and excluded from the nu-
cleus (Fig. 3; reference 36). In contrast, AIDF198A-GFP,
with a defective NES, was found in both the nuclear and
cytoplasmic compartments, a result consistent with free dif-
fusion of a 52-kD protein that is neither actively imported
into nor exported from the B cell nucleus (Fig. 3). We
conclude that the AID NES controls the subcellular local-
ization of AID in B cells.
The AID NES Limits SHM in 3T3-NTZ Cells. To de-
termine whether the NES affects AID activity, we mea-
sured mutation in E. coli (25). Indicator uracil-DNA glyco-
sylase-deficient E. coli carry an inactive kanamycin (Kan)
gene (kanL94P, TTGL94→CCAP94) that can be reverted to
Kan resistance (KanR) by C to T mutation. Thus, Kan-
resistant colonies are a measure of the cytidine deamination
activity of AID. AIDF198A and wild-type AID were ex-
pressed at comparable levels in E. coli as determined by
Western blotting (Fig. 4 A) and showed a slightly higherNuclear Export of Activation-induced Deaminase 1240
in AID and a maximum of 16 mutations per clone in
AIDF198A (Fig. 5 D). In addition, 10 out of 77 GFP clones
sequenced from AIDF198A showed deletions ranging from
11–45 bp, but there were no deletions in 79 clones from
AID-expressing cells (Fig. 5 E). Despite the increase in rate
of mutation, AIDF198A showed the same hotspot preferences
as AID (Fig. 5 E). We conclude that nuclear export limits
AID-mediated SHM in 3T3-NTZ cells.
Switch Region Hypermutation and CSR in B cells. To de-
termine whether nuclear export also regulates SHM and
CSR in B cells, we measured the rate of CSR and hyper-
mutation of the switch    region in B cells expressing
AIDF198A. AID /  B cells infected with retroviruses encod-
ing either AID or AIDF198 and a GFP indicator were stimu-
lated with LPS plus IL-4 to undergo CSR and switch  
mutation (Fig. 6 A). 72 h after infection, CSR was mea-
sured by surface IgG1 expression and mutation was evalu-
ated by cloning and sequencing a region 5  of the Ig 
switch repeats from IgG1-expressing B cells. AID /  B
cells showed 3.5-fold lower levels of AIDF198A protein than
wild-type AID by Western blotting (Fig. 6 B), and lower
levels of CSR (Fig. 6 C; 60% of AID in n   3 experi-
ments). AIDF198A also showed a decrease in the number of
clones that contained mutations in the switch   region rel-
ative to AID (Fig. 6 D; 17 vs. 32%, respectively, P  
0.006). However, within each switch   region that was
mutated, the average number of mutations was similar in
that AIDF198A had 1.7 compared with 1.4 for AID (Fig. 6
D; P   0.3), with a similar distribution, spectrum, and
hotspot preference (Fig. 6 E).
Discussion
AID initiates SHM and CSR by deaminating cytidine
residues in ssDNA, a reaction that has the potential to pro-
duce significant collateral genomic damage. Nevertheless,
most B cells expressing AID do not suffer widespread mu-
tation or chromosome instability (46–48). Our experiments
show that AID contains an NES that controls its subcellular
localization and limits nonphysiologic target gene mutation
in fibroblasts. However, the NES does not appear to im-
pact on Ig switch region mutation in B lymphocytes.
We have not addressed the question of how AID gets
into the nucleus. In this study we found no direct evidence
for a constitutive NLS in AID. By itself, AID is small
enough to passively diffuse into the nucleus. We used a
PK-GFP indicator, which is too large to enter the nucleus
by diffusion, to discriminate between active transport and
Figure 6. SHM by NES mutant AID in B cells. (A) Representation of retroviral vectors used to infect B cells. (B) AID and AIDF198A protein expression
in AID /  B cells after 3 d of culture measured by Western blotting of whole cell extracts. Anti-PK Western blot served as a loading control. The results
are representative of three independent experiments. (C) CSR in AID /  spleen B cells expressing AID or AIDF198A. Dot plots show IgG1 surface
expression on AID or AIDF198A-expressing AID /  B cells that had been stimulated with LPS plus IL-4 for 3 d. Numbers indicate the percentage of
GFP  cells that were IgG1 . The results are representative of three independent experiments. (D) Proportion of GFP sequences cloned from AID or
AIDF198A-expressing, surface IgG1  AID /  B cells 3 d after retrovirus infection carrying a different number of mutations. Segment sizes in the pie charts
are proportional to the number of sequences carrying the number of mutations indicated in the periphery of the charts. The total number of independent
sequences analyzed is indicated in the center of each chart. Deletions, duplications, and insertions were excluded from this analysis. (E) Comparison of S 
sequences cloned from AID or AIDF198A-expressing, surface IgG1  AID /  B cells 3 d after retrovirus infection. Single nucleotide substitutions are indi-
cated above (AID) or below (AIDF198A) the authentic S  sequence. Hollow boxes indicate deletions. WRC (R, purine; W, A or T) hotspots (reference
70) are underlined.McBride et al. 1241
diffusion (40, 41). AID was unable to transport the PK-
GFP to the nucleus even when nuclear export was blocked
by LMB. We also failed to find nuclear accumulation
of AID in cells expressing an amino terminal–tagged
NES mutant AID (GFP-AIDF198A; Fig. 1). Instead, GFP-
AIDF198A was found in the cytoplasm and nucleus of fibro-
blasts and B cells undergoing CSR, a result consistent with
passive diffusion.
Although we see no evidence of active import, the
amino terminus of AID contains an amino acid sequence
that resembles a bipartite NLS, and it has been reported
that this region is required for the nuclear accumulation of
AID (44). AID is homologous to APOBEC-1, an mRNA
editing enzyme (49), and an analogous basic region
required for nuclear accumulation is also found in the
amino terminus of APOBEC-1 (50–52). This region of
APOBEC-1 is involved in nuclear accumulation, but it
does not appear to function as an autonomous NLS be-
cause it cannot direct heterologous proteins such as PK or
GST to the nucleus (50–52). Mutagenesis studies on this
region of APOBEC-1 reveal that the arginine and lysine
residues, normally the critical elements of a bipartite NLS,
can be mutated without loss of nuclear accumulation (50,
52). Furthermore, the carboxyl terminal domain (residues
97–172) of APOBEC-1 is also critical for nuclear accumu-
lation APOBEC-1 (51). All of these characteristics indicate
that if APOBEC-1 has an NLS, it certainly is an atypical
one. A recent study by Ito et al. (44) also suggested that the
same amino terminal region of AID plays a critical role in
localizing AID to the nucleus. However, the authors used
an AID-GFP, which differed from ours in the linker se-
quence between AID and GFP, and because of its size, did
not discriminate between active nuclear transport and pas-
sive diffusion with nuclear retention (44). If the studies of
APOBEC-1 serve as any indication, then the regulation of
AID nuclear transport might be a complex process.
In fibroblasts, absence of the AID nuclear export was as-
sociated with increased SHM of a nonantibody substrate,
but the hotspot target preference and the nature of the mu-
tations did not change. The increase in mutation was due
to an increase in the frequency of mutated genes and an in-
crease in the absolute number of mutations per altered se-
quence. In addition, we found increased numbers of dele-
tions of the target gene. We interpret this as due to a
greater frequency of AID-induced lesions that increase the
probability of a double strand DNA break.
We did not find increased CSR or mutation in the 5  of
switch region in B cells stimulated with LPS and IL-4
when we blocked nuclear export. Thus, increasing the nu-
clear concentration of AID is sufficient to enhance muta-
tion of a nonantibody gene in fibroblasts but not on a nor-
mal target of AID, the switch   region in B cells.
The NES in AID overlaps a region that is essential for
CSR but not required for SHM in humans and mice (resi-
dues 189–198; references 37 and 53). Consistent with this
observation, AIDF198A shows decreased CSR (60% of wild-
type; Fig. 6) and a more dramatic defect is seen with dele-
tion of the three carboxyl terminal amino acid residues
(10% of wild-type; reference 44), underlining the impor-
tance of the carboxyl terminus of AID in CSR. AID 189–198
differs from AIDF198A in that it shows a 10-fold increase in
catalytic activity in E. coli when compared with wild-type
AID, and it has lost the ability to mediate CSR entirely.
Despite nuclear trapping by loss of the NES and the 10-
fold increase in catalytic activity of AID 189–198, this and re-
lated mutants do not show enhanced Ig switch region or Ig
V region SHM (37, 53). The function of the last 10 amino
acids in CSR has not been determined, but this region of
the molecule does not appear to be essential for targeting to
the antibody switch regions or in limiting SHM because B
cells expressing AID 189–198 show normal switch   lesion
formation. It has been proposed that the carboxyl terminus
functions in the synapsis phase of the CSR reaction (37).
Transcription targets SHM to a 1.5–2 kb region starting
at the 5  boundary of the variable region exon (54, 55),
but the sequence of the exon does affect the rate of muta-
tion (56, 57). Furthermore, there is no promoter specific-
ity for SHM because non-Ig promoters are sufficient for
SHM when combined with Ig enhancers (58–61). Tran-
scription also targets CSR to specific switch regions by in-
tronic promoters 5  of switch DNA (62, 63), and CSR is
absent after deletion of these promoters or their regulatory
elements (64–67). How transcription targets AID to anti-
body genes is still to be determined, but the finding that in
E. coli transcription facilitates SHM by exposing ssDNA
suggests that one link between mutation and transcription
might be that RNA polymerase uncovers the ssDNA tem-
plate for AID (25). Thus, highly transcribed genes loaded
with many molecules of polymerase would display more
ssDNA making them better substrates for AID. This idea is
supported by experiments in transfected cell lines overex-
pressing AID where non-Ig genes are targeted for muta-
tion by a mechanism that is directly dependent on the rate
of target gene transcription (11, 12, 68, 69). Our experi-
ments show that increasing the nuclear concentration of
AID in these cells also increases the amount of SHM and
that regulated nuclear export of AID might be one of the
molecular devices that restricts AID activity on nonanti-
body genes in fibroblasts. In contrast, in B cells, increasing
nuclear AID does not increase Ig gene mutation and
therefore mutation must be limited either by target gene
availability, i.e., the rate of Ig gene transcription, or yet to
be identified AID-interacting factors.
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